208 related articles for article (PubMed ID: 16758553)
1. FDA makes final approvals.
AIDS Patient Care STDS; 2006 May; 20(5):381. PubMed ID: 16758553
[No Abstract] [Full Text] [Related]
2. FDA notifications. Complera approved.
AIDS Alert; 2011 Nov; 26(11):130-1. PubMed ID: 22164521
[No Abstract] [Full Text] [Related]
3. Generic Truvada approved.
AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
[No Abstract] [Full Text] [Related]
4. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
5. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
6. The art of managing human immunodeficiency virus infection: a balancing act.
Reiss P
Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
[No Abstract] [Full Text] [Related]
7. Gilead AIDS pill effective in study with weekends off.
AIDS Read; 2008 Dec; 18(12):593. PubMed ID: 19123271
[No Abstract] [Full Text] [Related]
8. Recent FDA approvals and changes.
AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
[No Abstract] [Full Text] [Related]
9. Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Expert Rev Clin Immunol; 2010 Mar; 6(2):186. PubMed ID: 20402380
[No Abstract] [Full Text] [Related]
10. Prevention. Using PrEP cost-effective in high-risk MSM groups.
AIDS Policy Law; 2012 Jun; 27(7):1. PubMed ID: 22803211
[No Abstract] [Full Text] [Related]
11. European CHMP issues positive opinion for Atripla.
AIDS Patient Care STDS; 2007 Nov; 21(11):890. PubMed ID: 18338431
[No Abstract] [Full Text] [Related]
12. FDA notifications. Two tenofovir containing products are approved.
AIDS Alert; 2006 Jun; 21(6):71. PubMed ID: 16795142
[No Abstract] [Full Text] [Related]
13. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
[No Abstract] [Full Text] [Related]
14. FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
AIDS Alert; 2009 Oct; 24(10):119-20. PubMed ID: 20034141
[No Abstract] [Full Text] [Related]
15. FDA approves Viread for HIV-1 infection.
FDA Consum; 2002; 36(1):5. PubMed ID: 11881601
[No Abstract] [Full Text] [Related]
16. Viread gets FDA nod.
Rodriquez E
Posit Living; 2001 Dec-2002 Jan; 10(7):33. PubMed ID: 11808509
[No Abstract] [Full Text] [Related]
17. FDA grants tentative approval to first generic version of antiretroviral Viread.
AIDS Patient Care STDS; 2008 Jan; 22(1):86. PubMed ID: 18453039
[No Abstract] [Full Text] [Related]
18. Vaccine briefs.
McEnery R; Kresge KJ
IAVI Rep; 2010; 14(6):18-9. PubMed ID: 21384772
[No Abstract] [Full Text] [Related]
19. Initial results reported on raltegravir once-daily dosing.
AIDS Patient Care STDS; 2011 Feb; 25(2):123. PubMed ID: 21370546
[No Abstract] [Full Text] [Related]
20. Tapping into combination pills for HIV.
Hughes B
Nat Rev Drug Discov; 2009 Jun; 8(6):439-40. PubMed ID: 19483700
[No Abstract] [Full Text] [Related]
[Next] [New Search]
